INTRODUCTION
The HIV epidemic still poses major public health issues worldwide. The Joint United Nations Program on HIV/AIDS has estimated that 35 million people are living with HIV in 2013. The pandemic is dominated by HIV-1, while cases with HIV-2 infection are largely limited to West Africa. The number of infected people is estimated to be approximately 1 to 2 million (1). HIV-2 infection has milder outcomes than HIV-1 infection (2) , and 75z of HIV-2-infected patients have been found to be asymptomatic (3) .
HIV-1 is classified into 4 groups (M, N, O, and P) (4), with group M being the cause of the worldwide pandemic. HIV-2 is divided into 8 groups (A-H) (5-8); among these, groups A and B are epidemic, while cases of the other HIV-2 groups are rare (8, 9) . The recombinant HIV-2 CRF01_AB was recently identified (10) .
In Japan, a number of HIV-2 infection cases have been reported (10) (11) (12) . Therefore, both HIV-1 and HIV-2 tests are currently performed for diagnosis. In Japan, the laboratory testing guidelines recommend that HIV-1 infection should be confirmed using both western blotting (WB) and nucleic acid amplification tests (NATs), while HIV-2 infection can only be confirmed using WB after a positive screening antibody/ antigen test result. Because WB occasionally shows false-negative results and cross-reactions between HIV-1 and HIV-2, it is difficult to distinguish coinfection from false-positive results for HIV-2 using current immunological assays.
Although NATs show fewer false-negative results and cross-reactions between HIV-1 and HIV-2 than WB, an HIV-2 NAT is not commercially available. Numerous HIV-2-specific in-house assays have been proposed and compared in an international collaboration related to HIV-2 infection (the ACHIEV2E collaboration) (13) . However, these assays have not been designed to test both HIV-1 and HIV-2. In this study, we developed a qualitative real-time PCR assay for the detection of both HIV-1 RNA and HIV-2 RNA using bovine leukemia virus (BLV) as an internal standard.
MATERIALS AND METHODS
Viruses and plasma samples: The World Health Organization (WHO) international standards for HIV-1 RNA (code 97/650) (14) and HIV-2 RNA (code 08/150) (15) were purchased from the National Institute for Biological Standards and Control (Potters Bar, UK). The international HIV-1 and HIV-2 standards are freezedried pooled plasma containing virus isolated from infected individuals. The virus concentrations of these standards were determined and expressed in International Units (IU): 5.56 log 10 IU/vial for HIV-1 (14) and 1,000 IU/vial for HIV-2 (15). The HIV-1 subtype B strain 8E5 (16) and the HIV-2 subtype A strain ROD (17, 18) were obtained from the National Institute of Infectious Diseases (Tokyo, Japan). Twenty-nine plasma samples from HIV-1 seropositive patients (3 infected with subtype A, 7 with subtype B, 3 with subtype C, 2 with subtype D, 2 with subtype F1, 1 with subtype K, 8 with CRF01_AE, and 3 with CRF02_AG) and 100 plasma samples from HIV seronegative persons were provided by the Kanagawa Prefectural Institute of Public Health, which collaborates with several HIV-special-ized hospitals and clinics in Kanagawa and Tokyo, Japan. Furthermore, 24 clinical blood samples were obtained from HIV-1 seropositive treatment-naive patients at Keio University Hospital in Tokyo. The Anti-HIV-2 Performance Panel PRF203 (SeraCare Life Sciences, Milford, MA, USA), which includes 10 undiluted 1.0-ml plasma samples from different individuals positive for anti-HIV-2, was used as the source of HIV-2. BLV used as an internal standard (IS) was provided by Dr. Aida (RIKEN, Saitama, Japan), which is available from American Type Culture Collection (VR-1355, Manassas, VA, USA). Pooled human plasma (acid citrate dextrose, Cosmo Bio, Tokyo, Japan) was used as a negative control and to dilute seropositive plasma samples. All samples were stored at -809 C until use.
Real-time PCR for detection of HIV-1 and HIV-2 RNA: Five hundred microliters of plasma was spiked with 500 particle units (pu) of BLV (a particle unit was defined as described below) and then centrifuged at 15,000 rpm and 49 C for 1 h. The supernatant was discarded and 20 ml remained. After adding 180 ml of physiological saline, RNA was purified using the QIAamp MinElute Virus Spin Kit (Qiagen, Hilden, Germany) by elution in 60 ml according to the manufacturer's instructions, excluding the drying step of the membrane at 569 C for 3 min with the lid open to avoid contamination with the targeted RNA or DNA.
The primers and probe for HIV-1 were designed for the gag p24 region as previously described (19) The eluted RNA solution was divided into 3 portions (20 ml each) on a 96-well plate; to each well, 1 of 3 different master mixtures (10 ml) containing the primers and probe specific for HIV-1, HIV-2, or BLV was added. Real-time reverse transcription-PCR (RT-PCR) was then performed in a 30-mL reaction mixture containing 1 × PCR buffer (attached to Platinum StepOnePlus TM real-time PCR system (Applied Biosystems) was used. The cycling parameters were 509 C for 15 min, 959 C for 20 s, and 50 cycles of 949 C for 1 s, 609 C for 10 s, and 729 C for 10 s. The quantification cycle (Cq), which defines the thermal cycle number when amplification of a PCR product is first detected, was determined using StepOnePlus TM RealTime PCR Software v2.1 with default parameters.
Estimation of viral RNA concentration in virus suspensions: The viral RNA concentrations in the HIV-1 8E5, HIV-2 ROD, and BLV viral suspensions were estimated as follows. RNA was purified from a fixed volume of the virus suspension using the QIAamp MinElute Virus Spin Kit as described above. The RNA solution was serially diluted by 2-fold in distilled water and subjected to RT-nested PCR (see below) to assess the dilution rate at the endpoint. Next, the RNA solution diluted at the endpoint dilution rate was analyzed in 30 replicates by RT-nested PCR. The copy number of viral RNA per reaction was assessed using the null equation of Poisson distribution (19) . The particle unit was defined as half of the RNA copy number to account for the dimeric RNA in a retroviral particle.
RT-nested PCR was performed as follows. Firstround forward and reverse primers for HIV-1 and HIV-2 were the same as those used for real-time RT-PCR. First-round forward and reverse primers for BLV were 5?-TGAGACCCTCGTGCTCAGCT-3? (227-246) and 5?-AACCACCCTCCAAACCGTG-3? (317-335). Second-round forward and reverse primers for HIV-1 were 5?-GAGGAAGCTGCAGAATGGGA-3? (1408-1427) and 5 ? -GTTCTCTCATCTGGCCTGGTG-3 ? (1460-1480), respectively; those for HIV-2 were 5 ? -CTGGGAGGTTCTCTCCAGCA-3? (34-53) and 5?-ACTGGTGAGAGTCTAGCAGGGAA-3 ? (75-97), respectively; those for BLV were the same as those used for real-time RT-PCR. First-round PCR was performed in a 50-ml reaction mixture containing 1 × PCR buffer, 3 mM of MgCl 2 , 0.2 mM of each dNTP, 0.2 mM of forward and reverse primers, 4 U of RNasin  RNase Inhibitor, 20 U of SuperScript  III Reverse Transcriptase, and 1 U of Platinum  Taq DNA Polymerase (Invitrogen). Second-round PCR was performed using 1 ml of the first-round PCR product in a 25-ml reaction mixture containing 1 × PCR buffer, 3 mM of MgCl 2 , 0.2 mM of each dNTP, 0.2 mM of forward and reverse primers, and 0.5 U of Platinum  Taq DNA Polymerase. The cycling parameters for RT and first-round PCR were 509 C for 10 min, 949 C for 2 min, 5 cycles of 949 C for 5 s, 489 C for 10 s, and 729 C for 15 s, and 25 cycles of 949 C for 5 s, 609 C for 15 s, followed by 729 C for 1 min; those for second-round PCR were 949 C for 2 min, 5 cycles of 949 C for 5 s, 489 C for 10 s, and 729 C for 15 s, and 20 cycles of 949 C for 5 s, 609 C for 15 s, followed by 729 C for 1 min. The PCR products were analyzed by 2.0z agarose gel electrophoresis using LE Agarose (BM Bio, Tokyo, Japan).
Determination of lower limit of detection: The Cross-reactivity and interference: Cross-reactivity between HIV-1 and HIV-2 was assessed using a human plasma sample containing 250,000 pu/ml HIV-1 8E5 or containing 250,000 pu/ml HIV-2 ROD. Interference between HIV-1 and HIV-2 RNA was examined using plasma samples containing 50 pu/ml ROD and a sample containing 2,500, 25,000, and 250,000 pu/ml 8E5, as well as plasma samples containing 50 pu/ml 8E5 and a sample containing 2,500, 25,000 and 250,000 pu/ml ROD.
The AcroMetrix  Inhibition Panel (Life Technologies, Foster City, CA, USA) was used to assess the effects of potential interfering substances and clinical conditions including heparin, EDTA, hemolysis, lipemia, and icterus on the HIV-1 and HIV-2 RNA quantification. The HIV-1 and HIV-2 international standards were added to 500 ml of each panel member to achieve final concentrations of 1,700 IU/ml and 150 IU/ml, respectively.
Statistical analysis: Statistical analysis was performed using SPSS Statistics version 22 (SPSS, Inc., Chicago, IL, USA).
RESULTS

Optimization of real-time RT-PCR conditions:
We first determined the optimal concentrations of reagents, primers, and probes for performing real-time RT-PCR using 500 pu/ml HIV-1 8E5 and HIV-2 ROD virus suspensions by examining the Cq values and fluorescent intensities. The PCR conditions published by Kato et al. (20) were used as a starting point for optimization of these concentrations. The optimal concentration of MgCl 2 was 4 mM among the concentrations tested in the range 1.5-7 mM; that of each dNTP was 0.2 mM in the range 0.05-0.8 mM; that of primers was 0.2 mM in the range 0.05-0.4 mM; that of probes 0.16 mM of probe in the range 0.04-0.32 mM; and the optimal quantity of Platinum  Taq was 4 U in the range 2-8 U. Since no significant change in Cq or fluorescence intensity were observed when the quantity of SuperScript The StepOnePlus TM real-time PCR system includes 2 thermal cycling modes, standard and fast. We compared the Cq values and fluorescent signal intensities in the 2 modes using both 8E5 and ROD in the range 0-10,000 pu/ml and found no significant difference. We chose the fast mode to reduce the time required for the reaction. Thereafter, we found that the insertion of a 729 C elongation step after a 609 C step in the fast mode enhanced amplification intensity. When a small quantity of virus particles (e.g., 10 pu) was tested, 50 thermal cycles were required until a plateau of fluorescence intensity was reached. The optimized cycling parameters are described in the Materials and Methods.
At early developmental stages, we attempted to detect HIV-1 RNA and HIV-2 RNA in a single well by using 2 pairs of primers and 2 probes labeled with different fluorophores (FAM and NED) specific for HIV-1 and HIV-2. However, significant interference was observed when the HIV-1 primers were added to the reaction mixture to test HIV-2 RNA: the fluorescence intensity was reduced in a dose-response manner, while the Cq value remained unchanged (Fig. 1) . Furthermore, the addition of FAM-labeled HIV-1 probe to the reaction mixture to test for HIV-2 RNA using the NED-labeled HIV-2 probe increased the Cq value by approximately 2-fold (Fig. 2) . The opposite experiments showed similar results (data not shown). Therefore, we detected HIV-1 RNA, HIV-2 RNA, and IS in separate wells to increase the sensitivity.
Performance of real-time PCR: Although we did not intend to develop a quantitative assay for HIV-1 and HIV-2 RNA, the Cq values in real-time PCR relative to the concentrations of HIV-1 8E5 or HIV-2 ROD showed a good linearity in the range 5-5,000 pu/ml (Fig. 3) . In total, 500 pu of BLV was used as the IS. The mean and standard deviation of the Cq values were 32.15 ± 1.29. The presence of IS did not affect the Cq values of the HIV-1 8E5 and HIV-2 ROD at concentrations of 5, 50, and 500 pu/ml and had no influence on the baseline of a blank plasma sample (data not shown).
Next, we examined whether the co-existence of HIV-1 and HIV-2 affected the detection of either of the viruses. The Cq values for 50 pu/ml HIV-1 8E5 were not changed by the presence of 2,500, 25,000, or 250,000 pu/ml HIV-2 ROD and vice versa (Table 1) .
Next, we examined the effects of common interfering substances found in the blood using the AcroMetrix  Inhibition Panel. The panel components were mixed with HIV-1 or HIV-2 to a final concentration of 500 pu/ml. No significant decrease was observed except in heparinized plasma spiked with HIV-2, in which the Cq value was increased by 2.51-fold (Table 2) .
Lower limit of detection: We tested 8 replicates of the WHO international standards for HIV-1 and HIV-2 diluted with seronegative human plasma at 6 concentrations ranging from 1.7 to 67 IU/ml for HIV-1 and 0.16 to 6.2 IU/ml for HIV-2 to determine the LOD. Based on the results (Table 3) , the LOD was determined to be 54 IU/ml (95z CI, 40-73 IU/ml) for HIV-1 and 5.0 IU/ml (95z CI, 4.2-5.9 IU/ml) for HIV-2.
Performance on plasma samples: Twenty-nine HIV-1 seropositive plasma samples and 100 HIV seronegative plasma samples from the Kanagawa Prefecture Institute of Public Health were used to determine the performance of the present assay; 27 of the 29 seropositive samples were assayed using Cobas TaqMan  HIV-1 version 1.0 (Roche Molecular Systems, Pleasanton, CA, USA). All 20 samples in which the HIV-1 RNA level was determined to be 40 copies/ml provided positive results, and 6 of 7 samples in which the HIV-1 RNA level was detectable but ＜40 copies/ml showed positive 2) : Provided by the manufacturer. BLQ, below the limit of quantification; BLD, below the limit of detection.
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Detection of HIV-1 and HIV-2 RNA by Real-Time PCR results ( Table 4 ). The Cq values of our real-time PCR assay were correlated with the viral loads determined using Cobas TaqMan  (r ＝ 0.782, P ＜ 0.001), despite that the samples comprised various HIV-1 subtypes, suggesting that the detection ability of the present assay may not be affected by differences in subtype. The other 2 samples that had not been assayed using Cobas TaqMan  were positive according to the present assay. All 100 seronegative samples showed negative results. In addition, all 24 plasma samples from treatment-naä ƒve HIV-1 subtype B-infected patients from Keio University Hospital whose viral loads ranged from 4,900 to 460,000 copies/ml produced HIV-1-positive results. In total, 51 of 52 HIV-1 seropositive samples showed positive results in our assay. All of the above samples tested negative for HIV-2.
The SereCare Anti-HIV-2 Performance Panel was used to examine the performance of the assay for HIV-2 RNA. All 4 samples with 160 copies/ml HIV-2 RNA and 3 of the 6 samples with below the limit of quantification or below the LOD of HIV-2 RNA showed HIV-2-positive results (Table 5) . HIV-1 positive signals were not observed for any of the panel samples.
DISCUSSION
In Japan, HIV diagnosis in the clinical setting is typically performed using the 4th generation HIV immunoassay as a screening test, followed by HIV-1 and HIV-2 WB and HIV-1 NAT as confirmatory tests. In this HIV diagnostic procedure, it is difficult to distinguish HIV-2 infection from HIV-1 infection or HIV-1/2 dual infection because cross-reactions between HIV-1 and HIV-2 are frequently observed in WB results. Another limitation of the current HIV diagnostic scheme is the lack of commercially available NAT for HIV-2. Therefore, we developed an HIV-1 and HIV-2 detection assay using real-time PCR. The LOD of this method was 54 IU/ml for HIV-1 and 5.0 IU/ml for HIV-2. Cross-reactions and inhibition were not observed when up to 250,000 pu of HIV-1 and HIV-2 coexisted.
The conversion factor between HIV-1 RNA copies/ml and HIV-1 IU/ml is known to be 0.6 or 0.51 copies/IU (21) . Therefore, the LOD of our assay for HIV-1 RNA is equivalent to 32 or 28 copies/ml, which is close to those of commercially available HIV-1 RNA quantification assays, e.g. Cobas TaqMan  HIV-1 version 2.0 has an LOD of 20 copies/ml. Regarding HIV-2, Chang et al. (22) reported an HIV-2 quantification assay with an LOD of 8 copies/ml or 53 IU/ml, and Styer et al. (23) reported another assay with an LOD of 31.5 IU/ml. These LODs are more than 6-fold higher than that of our assay.
BLV was used as an IS to minimize the risk of falsenegative results, which can be caused by a technical failure or the inclusion of inhibitory materials in individual samples. Similar to HIV, BLV is a retrovirus, but is not pathogenic to humans. The addition of BLV into plasma samples did not affect the purification, extraction, or RT-PCR amplification of HIV-1 and HIV-2. BLV may be one of the most suitable internal standards for testing HIV-1 and HIV-2.
Pripuzova et al. (24) reported a simultaneous detection assay for HIV-1, HIV-2, and some other viruses using real-time PCR with SYBR Green, but their assay failed to amplify subtype F (Group M) and group O isolates. Our assay detected subtype F, but it may not be able to detect group O isolates because the primers were designed to hybridize to sequences of variants belonging to only the HIV-1 group M subtypes (19) .
The present study has several limitations. First, a limited number of HIV-2 seropositive samples were tested. Additional HIV-2 samples should be assayed to validate the assay. Second, few HIV-1 and HIV-2 coinfected samples were used, and no case of coinfection has been reported in Japan. Third, HIV-2 subtype B samples were not tested in this study. However, it is likely that HIV-2 strains can be detected using our assay because the nucleotide sequences of all HIV-2 subtype B strains determined thus far are identical to those of the forward and reverse primers and probe used for the real-time PCR.
In this study, we found that the sensitivity of the assay decreased when multiplex real-time PCR was used ( Figs. 1 and 2 ). This may be because of competition among the primers and probes. The sensitivity also depended on the fluorescent dye used (data not shown). Therefore, to achieve a higher sensitivity, we divided the extracted RNA solution into 3 portions and used each portion to detect HIV-1 RNA, HIV-2 RNA, or BLV RNA separately.
The use of NAT for HIV-2 RNA to diagnose HIV infection is controversial because HIV-2 RNA is undetectable in nearly half of HIV-2 infected patients (25) . It is generally recognized that proviral DNA is more frequently detected than viral RNA in HIV-2 infection, e.g., 94z vs. 56z (26) or 80z vs. 45z (27) , while recently developed sensitive NATs for HIV-2 RNA showed higher detection frequencies of 59z (22) and 73z (23) . Although the detection of proviral HIV-2 DNA would be a more suitable confirmatory test for samples with positive or indeterminate bands on western blotting, it is advantageous to use the same plasma sample to test for both HIV-1 and HIV-2 RNA because this approach reduces sample processing. When HIV-2 RNA is undetected using the current assay, additional NAT for HIV-2 DNA or testing of follow-up samples may be required.
Here, we describe a highly sensitive and accurate assay to detect HIV-1 and HIV-2 RNA in parallel. This assay will be a valuable tool for the differential diagnosis of HIV-1 and HIV-2 infections.
